Cracking The Code: Understanding Analyst Reviews For ResMed
Portfolio Pulse from Benzinga Insights
Analysts have updated their ratings and price targets for ResMed (NYSE:RMD) over the past three months, with a mix of bullish and indifferent stances. The average 12-month price target is now $188.0, up from $175.25, with a high estimate of $215.00 and a low of $160.00. ResMed's financial performance is strong, with a revenue growth rate of 16.0%, a net margin of 19.91%, an ROE of 5.24%, an ROA of 3.25%, and a low debt-to-equity ratio of 0.35. The company is well-positioned in the respiratory care device market, with a focus on digital health and a growing market due to increasing diagnoses of sleep apnea.
January 25, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ResMed has received updated analyst ratings and price targets, with a current average price target of $188.0, reflecting a positive sentiment. The company's strong financial performance and strategic focus on digital health in the respiratory care market support a bullish outlook.
The increase in the average price target to $188.0, along with positive financial indicators such as revenue growth and profitability, suggest a bullish sentiment among analysts. This, combined with ResMed's strategic positioning in a growing market, is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100